References
- Calais Da Silva F, Marquis P, Deschaseaux P, Ginest JL, Cauquil J, Patrick DL. Relative importance of sexuality and quality of life in patients with prostatic symptoms. Results of an International study. Eur Urol 1997; 31: 272–80
- De la Rosette JJMCH, Alivizatos G, Madersbacher S, Perachino M, Thomas D, Desgrandchamps F, et al. EAU guidelines on benign prostatic hyperplasia (BPH). Eur Urol 2001; 40: 256–63
- McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Logan Holtgreve H, et al. for the finasteride long-term efficacy and safety study group (PLESS). The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998; 338: 557–63
- Roehrborn CG, Boyle PJ, Nickel C, Hoefner K, Andriole G, on behalf of the ARIA3001, ARIA3002 and ARIA3003 study investigators. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002;60:434–41.
- O'Leary MP, Roehrborn C, Andriole G, Nickel C, Boyle P, Hofners K. Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reducatse inhibitor. BJU Int 2003; 92: 262–6
- Beck JR, Pauker SG. The Markov process in medical diagnosis. Med Decis Making 1983; 3: 419–58
- Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13: 322–7
- Barry MJ, Fowler FJ, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, et al. Measuring disease-specific health status in men with benign prostatic hyperplasia. Med Care 1995; 33: AS145–55
- Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology 1998; 51: 892–900
- Lepor H. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group. Urology 1998; 51: 901–6
- Narayan P, Tewari A. A second phase III multicenter placebo controlled study of 2 dosages of modified release Tamsulosin in patients with symptoms of benign prostatic hyperplasia. J Urol 1998; 160: 1701–6
- Narayan P, Lepor H. Long-term, open label, Phase III multicenter study of tamsulosin in benign prostatic hyperplasia. Urology 2001; 57: 466–70
- Hem KG. Economic consequences of sickness absence from work. Oslo: Sintef Unimed; 2000.
- Henriksson F, Fredrikson S, Jönsson B. Costs, quality of life and disease severity in multiple sclerosis—a cross-sectional study in Sweden. SSE/EFI Working Paper Series in Economics and Finance, No. 361. Stockholm: Stockholm School of Economics; 2000.
- Choong S, Emberton M. Acute urinary retention. BJU Int 2000; 85: 186–201
- Thompson IM, Goodman PJ, Tangen CM, Scott Lucia M, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215–24
- Kawakami J, Nickel C, Nikolopoulos P, Alamanis C, Zervas A, Dimopoulos C. Acute urinary retention and surgery for benign prostatic hyperplasia: the patient's perspective. Can J Urol 1999; 6: 819–22
- Mitropoulos D, Anastasiou I, Giannopoulou C, et al. Symptomatic benign prostatic hyperplasia: impact on the partners’ quality of life. Eur Urol 2002; 41: 240–4
- Normaltariff for privat spesialistpraksis. Takster gjeldende fra 1. Juli 2002. Den norske lægeforening 2002–3.
- Norwegian Medicines Agency price database, March 2003.